Key result
TPM2 downregulation distinguishes breast cancer from normal tissue with ~0.76 AUC.
Why the study?
The function of tropomyosin 2 (TPM2) in breast cancer was understudied, prompting exploration of its roles in breast cancer progression.
Does tropomyosin 2 (TPM2) expression correlate with clinicopathological progression and serve as a diagnostic biomarker in patients with breast cancer?
Observational (n=155)
Staining results independently assessed by two senior pathologists in a blind manner
No
Does tropomyosin 2 (TPM2) expression correlate with clinicopathological progression and serve as a diagnostic biomarker in patients with breast cancer?
TPM2 is significantly down-regulated in breast cancer and correlates with lymph node metastasis, high histological grade, poor recurrence-free survival, and immune infiltration, indicating its potential as a diagnostic and prognostic biomarker.
Answers are grounded in this paper and cite their sources.
TPM2 downregulation may support diagnostic evaluation in breast cancer; leaves open prognostic utility pending prospective validation.
Background: The function of tropomyosin 2 (TPM2) in breast cancer is still far understudied. In this study, we aim to explore the roles of TPM2 in breast cancer progression. Methods: This research included 155 breast cancer tissues. The expression of TPM2 was analyzed by immunohistochemical staining and grading. The mRNA expression of TPM2 in pan-cancer was analyzed with The Cancer Genome Atlas (TCGA) data plate form. The differential expression of TPM2 protein and the differential promoter methylation level of TPM2 between breast cancer tissues and normal breast tissues were analyzed by the UALCAN online database. The relationship between TPM2 and signaling pathways was interpreted by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) pathway enrichment analyses. The survival curve of TPM2 was analyzed across the Kaplan-Meier plotter online database. Furthermore, the relationship between TPM2 expression and infiltrating macrophages was validated through in vitro co-culture experiments. Results: TPM2 expression was significantly down-regulated in breast cancer samples. In addition, TPM2 expression was correlated with lymph node metastasis and high-grade histopathological morphology. The receiver operating characteristic (ROC) curve indicated that TPM2 expression could well distinguish between normal breast tissue and breast cancer tissue. TPM2 may have potential value in breast cancer diagnosis. Bioinformatics analysis illustrated that TPM2 was mainly involved in extracellular matrix organization, collagen fibril organization, cell junction assembly, focal adhesion, cAMP signaling pathway, estrogen signaling pathway, Wnt signaling pathway, and adaptive immune system. TPM2 expression was correlated with immune infiltrating cells and immune checkpoint molecules. Our in vitro co-culture experiments showed that the M2 macrophages could upregulate the expression of TPM2. Conclusion: TPM2 may play key roles in breast cancer occurrence and development, especially in cancer metastasis. TPM2 may be a potential biomarker for breast cancer diagnosis.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2024) conducted an observational in Breast cancer (n=155). TPM2 expression level (low IHC score < 6 vs high IHC score >= 6) vs. Normal adjacent breast tissues (n=51) or high TPM2 expression group (IHC score >= 6) was evaluated on Diagnostic accuracy of TPM2 expression in distinguishing breast cancer tissue from normal breast tissue (ROC AUC) (AUC 0.7572, 95% CI 0.6797-0.8346, p=<0.0001). TPM2 expression was down-regulated in breast cancer tissues and distinguished breast cancer from normal breast tissue with an AUC of 0.7572.
Synapse has enriched 10 related papers. Consider them for comparative context: